Host-Pathogen Interactions
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Engineering and Sustainable Crop Disease Management: Opportunities for Case-By-Case Decision-Making
sustainability Review Genetic Engineering and Sustainable Crop Disease Management: Opportunities for Case-by-Case Decision-Making Paul Vincelli Department of Plant Pathology, 207 Plant Science Building, College of Agriculture, Food and Environment, University of Kentucky, Lexington, KY 40546, USA; [email protected] Academic Editor: Sean Clark Received: 22 March 2016; Accepted: 13 May 2016; Published: 20 May 2016 Abstract: Genetic engineering (GE) offers an expanding array of strategies for enhancing disease resistance of crop plants in sustainable ways, including the potential for reduced pesticide usage. Certain GE applications involve transgenesis, in some cases creating a metabolic pathway novel to the GE crop. In other cases, only cisgenessis is employed. In yet other cases, engineered genetic changes can be so minimal as to be indistinguishable from natural mutations. Thus, GE crops vary substantially and should be evaluated for risks, benefits, and social considerations on a case-by-case basis. Deployment of GE traits should be with an eye towards long-term sustainability; several options are discussed. Selected risks and concerns of GE are also considered, along with genome editing, a technology that greatly expands the capacity of molecular biologists to make more precise and targeted genetic edits. While GE is merely a suite of tools to supplement other breeding techniques, if wisely used, certain GE tools and applications can contribute to sustainability goals. Keywords: biotechnology; GMO (genetically modified organism) 1. Introduction and Background Disease management practices can contribute to sustainability by protecting crop yields, maintaining and improving profitability for crop producers, reducing losses along the distribution chain, and reducing the negative environmental impacts of diseases and their management. -
Zoonotic Diseases Fact Sheet
ZOONOTIC DISEASES FACT SHEET s e ion ecie s n t n p is ms n e e s tio s g s m to a a o u t Rang s p t tme to e th n s n m c a s a ra y a re ho Di P Ge Ho T S Incub F T P Brucella (B. Infected animals Skin or mucous membrane High and protracted (extended) fever. 1-15 weeks Most commonly Antibiotic melitensis, B. (swine, cattle, goats, contact with infected Infection affects bone, heart, reported U.S. combination: abortus, B. suis, B. sheep, dogs) animals, their blood, tissue, gallbladder, kidney, spleen, and laboratory-associated streptomycina, Brucellosis* Bacteria canis ) and other body fluids causes highly disseminated lesions bacterial infection in tetracycline, and and abscess man sulfonamides Salmonella (S. Domestic (dogs, cats, Direct contact as well as Mild gastroenteritiis (diarrhea) to high 6 hours to 3 Fatality rate of 5-10% Antibiotic cholera-suis, S. monkeys, rodents, indirect consumption fever, severe headache, and spleen days combination: enteriditis, S. labor-atory rodents, (eggs, food vehicles using enlargement. May lead to focal chloramphenicol, typhymurium, S. rep-tiles [especially eggs, etc.). Human to infection in any organ or tissue of the neomycin, ampicillin Salmonellosis Bacteria typhi) turtles], chickens and human transmission also body) fish) and herd animals possible (cattle, chickens, pigs) All Shigella species Captive non-human Oral-fecal route Ranges from asymptomatic carrier to Varies by Highly infective. Low Intravenous fluids primates severe bacillary dysentery with high species. 16 number of organisms and electrolytes, fevers, weakness, severe abdominal hours to 7 capable of causing Antibiotics: ampicillin, cramps, prostration, edema of the days. -
The Resistance to Host Antimicrobial Peptides in Infections Caused by Daptomycin-Resistant Staphylococcus Aureus
antibiotics Communication The Resistance to Host Antimicrobial Peptides in Infections Caused by Daptomycin-Resistant Staphylococcus aureus Md Saruar Bhuiyan 1,† , Jhih-Hang Jiang 1,† , Xenia Kostoulias 1, Ravali Theegala 1, Graham J. Lieschke 2 and Anton Y. Peleg 1,3,* 1 Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC 3800, Australia; [email protected] (M.S.B.); [email protected] (J.-H.J.); [email protected] (X.K.); [email protected] (R.T.) 2 Australian Regenerative Medicine Institute, Monash University, Clayton, VIC 3800, Australia; [email protected] 3 Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC 3004, Australia * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Daptomycin is an important antibiotic for the treatment of infections caused by Staphylococcus aureus. The emergence of daptomycin resistance in S. aureus is associated with treatment failure and persistent infections with poor clinical outcomes. Here, we investigated host innate immune responses against clinically derived, daptomycin-resistant (DAP-R) and -susceptible S. aureus paired isolates using a zebrafish infection model. We showed that the control of DAP-R S. aureus infections was attenuated in vivo due to cross-resistance to host cationic antimicrobial Citation: Bhuiyan, M.S.; Jiang, J.-H.; peptides. These data provide mechanistic understanding into persistent infections caused by DAP-R Kostoulias, X.; Theegala, R.; Lieschke, S. aureus and provide crucial insights into the adaptive evolution of this troublesome pathogen. G.J.; Peleg, A.Y. The Resistance to Host Antimicrobial Peptides in Keywords: S. -
Chapter 2 Disease and Disease Transmission
DISEASE AND DISEASE TRANSMISSION Chapter 2 Disease and disease transmission An enormous variety of organisms exist, including some which can survive and even develop in the body of people or animals. If the organism can cause infection, it is an infectious agent. In this manual infectious agents which cause infection and illness are called pathogens. Diseases caused by pathogens, or the toxins they produce, are communicable or infectious diseases (45). In this manual these will be called disease and infection. This chapter presents the transmission cycle of disease with its different elements, and categorises the different infections related to WES. 2.1 Introduction to the transmission cycle of disease To be able to persist or live on, pathogens must be able to leave an infected host, survive transmission in the environment, enter a susceptible person or animal, and develop and/or multiply in the newly infected host. The transmission of pathogens from current to future host follows a repeating cycle. This cycle can be simple, with a direct transmission from current to future host, or complex, where transmission occurs through (multiple) intermediate hosts or vectors. This cycle is called the transmission cycle of disease, or transmission cycle. The transmission cycle has different elements: The pathogen: the organism causing the infection The host: the infected person or animal ‘carrying’ the pathogen The exit: the method the pathogen uses to leave the body of the host Transmission: how the pathogen is transferred from host to susceptible person or animal, which can include developmental stages in the environment, in intermediate hosts, or in vectors 7 CONTROLLING AND PREVENTING DISEASE The environment: the environment in which transmission of the pathogen takes place. -
STD (Sexually Transmitted Disease) Or STI (Sexually Transmitted Infection): Should We Choose? Janet Byron Anderson, Phd
STD (sexually transmitted disease) or STI (sexually transmitted infection): Should we choose? Janet Byron Anderson, PhD 1. Clinical foundation of the problem Another surprise: Documented incidence had shown Each of the terms—“sexual(ly)”, “transmitted”, “disease”, that the two routes of sexual transmission were male-to- and “infection”—is problematic independently, as this female and male-to-male. However, on 15 July 2016 the study will show. Moreover, co-occurring variants, used CDC reported the first case of suspected female-to-male as synonyms in English medical articles worldwide, ag- sexual transmission in New York City [4]. Since 2008, gravate the problem. The purpose of this study is to pro- then, the Zika virus has shown that it is now sexually pose a single term that can stimulate discussion about transmissible. “Transmissible” denotes a potential, and is whether the co-occurring variants are clinically and lin- distinct from “transmitted”, which denotes a reality. guistically justifiable—especially now, when STDs/STIs To say that Zika has proved to be transmissible through have become a global health problem, and public health sexual contact means that it can be transmitted through agencies in every country are scrambling to educate their sex but that it need not be (Zika remains a chiefly vec- citizens. [Until the presentation advances to the point tor-borne disease). However, cases reported since 2008 where the question posed in the title can be definitively document the reality of transmittedness through sexual answered, I’ll use the expression “STD/STI” or the terms contact. “illness(es)” and “condition(s)”.] The predisposing epidemiologic context will first be clar- This carefully differentiated language is used by the ified, for it sheds light on two of the problematic terms: European Centre for Disease Prevention and Control chiefly “transmitted” but also “sexual(ly)”. -
Sexually Transmitted Infections Treatment Guidelines, 2021
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized -
Transmission of SARS-Cov-2: Implications for Infection Prevention Precautions
Transmission of SARS-CoV-2: implications for infection prevention precautions Scientific brief 9 July 2020 This document is an update to the scientific brief published on 29 March 2020 entitled “Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precaution recommendations” and includes new scientific evidence available on transmission of SARS-CoV-2, the virus that causes COVID-19. Overview This scientific brief provides an overview of the modes of transmission of SARS-CoV-2, what is known about when infected people transmit the virus, and the implications for infection prevention and control precautions within and outside health facilities. This scientific brief is not a systematic review. Rather, it reflects the consolidation of rapid reviews of publications in peer-reviewed journals and of non-peer-reviewed manuscripts on pre-print servers, undertaken by WHO and partners. Preprint findings should be interpreted with caution in the absence of peer review. This brief is also informed by several discussions via teleconferences with the WHO Health Emergencies Programme ad hoc Experts Advisory Panel for IPC Preparedness, Readiness and Response to COVID-19, the WHO ad hoc COVID-19 IPC Guidance Development Group (COVID-19 IPC GDG), and by review of external experts with relevant technical backgrounds. The overarching aim of the global Strategic Preparedness and Response Plan for COVID-19(1) is to control COVID-19 by suppressing transmission of the virus and preventing associated illness and death. Current evidence suggests that SARS-CoV-2, the virus that causes COVID-19, is predominantly spread from person-to-person. -
Ask a Scientist: How Do People Become Infected with Germs?
One way to think about how living things get sick is to imagine a triangle. The three corners represent the environment... ...the host... All three aspects of this triangle must come ...and the cause of the disease, together for disease to occur. Disease the Agent. agents can be non-infectious or infectious. Non-infectious agents are non-living things that are toxic to the host, like radiation or chemicals... ...while infectious agents are organisms that invade a host to survive. Only infectious agents can spread, or transmit, between hosts. Infectious disease agents, otherwise known as pathogens, A person can become infected with a must infect a host pathogen when in the same environment in order to grow, or as the agent... replicate. Human pathogens, like viruses, bacteria, and parasites, evolved to infect people. Their survival is dependent on quickly invading, making more of themselves, and efficiently transmitting to others. If a pathogen gets past a host’s defenses, it will attempt to infect the host and begin replicating itself. ...and don’t have enough protection in the form The subsequent battle between Many cells will be destroyed as of physical barriers or the germs and the body’s germs kill them through replicating pre-existing immunity. immune system will cause the and as collateral damage from the symptoms of illness. activated immune cells. That’s just how one person gets infected, but how does disease spread? Well, if sick people go around sneezing and coughing without covering their mouth or frequently washing their hands... ...they are actually spreading pathogens all over the environment around them. -
Supporting North Carolina's Vaccination Efforts
Supporting North Carolina’s Vaccination Efforts Toolkit for Partner Organizations Updated June 17th, 2021 Current State of North Carolina COVID-19 Vaccinations: COVID-19 vaccines are available for free in North Carolina to everyone ages 12 and older. Those 18 and over can receive any of the three approved vaccines, while youth aged 12-17 may only receive the Pfizer vaccine. Individuals and CBOs may use the CDC Vaccine Finder to find locations that carry the Pfizer vaccine. While walk-in vaccinations are available, some locations may require appointments. In North Carolina, anyone can get vaccinated regardless of immigration status – getting vaccinated will not affect your immigration. No government-issued ID or insurance is required. Everyone can read the frequently asked questions on the DHHS website to learn more about vaccinations and what you can do after you’re vaccinated. Earning the Trust of North Carolinians: The injustices that drive the disparate impact of COVID-19 on historically marginalized populations (HMP)1 can also cause very legitimate reasons for community members to have questions about vaccines. That is why NCDHHS are working to partner with trusted leaders and organizations to provide accurate information to communities. NCDHHS is committed to earning the trust of North Carolinians related to the COVID-19 vaccine and beyond and building upon already established relationships. Organizations can consider the following strategies to support North Carolina’s vaccination efforts: 1. Share information about the COVID-19 vaccine: • Use the NCDHHS COVID-19 vaccine communications toolkit to make sure all North Carolinians have accurate and up-to-date information on the vaccine. -
Cationic Host Defense (Antimicrobial) Peptides Kelly L Brown and Robert EW Hancock
Cationic host defense (antimicrobial) peptides Kelly L Brown and Robert EW Hancock Members of the cationic host defense (antimicrobial) peptide Peptides are expressed with elements of immunity family are widely distributed in nature, existing in organisms Innate immunity is the most ancient form of immune from insects to plants to mammals and non-mammalian defense, conserved throughout the animal kingdom and vertebrates. Although many demonstrate direct antimicrobial vital to invertebrate host defenses. More recently dis- activity against bacteria, fungi, eukaryotic parasites and/or covered aspects of innate immunity — most notably, the viruses, it has been established that cationic peptides have a family of Toll-like receptors (TLRs) — have illuminated key modulatory role in the innate immune response. More the previously unrecognized complexity and heterogene- recent evidence suggests that host defense peptides are ity within the innate immune system. Many factors sup- effective adjuvants, are synergistic with other immune port important and diverse roles for antimicrobial effectors, polarize the adaptive response, and support wound peptides in immunity: the robust membership, broad healing. In addition, the mechanisms of action are being diversity in sequence and structure, thematic similarity unraveled, which support more effective implementation of of vertebrate and invertebrate antimicrobial peptides, derivatives of these endogenous peptides as therapeutic wide distribution in cells of the immune system (leuko- agents. cytes, Paneth -
Emerging Infectious Diseases
EMERGING INFECTIOUS DISEASES Javier Garau Hospital Universitari Mutua de Terrassa Universitat de Barcelona Spain Roma, 9-10 October 2008 Outline •Importance and impact of EIDs •Some definitions •Host range and EIDs and REIDs •Global trends •Getting ready for the future Leading causes of death worldwide. About 15 million (>25%) of 57 million annual deaths worldwide are the direct result of infectious disease. (http://www.who.int/whr/en) Not included the additional millions of deaths that occur as a consequence of past infections (for example, streptococcal rheumatic heart disease), or because of complications associated with chronic infections, such as liver failure and hepatocellular carcinoma in people infected with hepatitis B or C viruses. EIDS: PREPARING FOR THE FUTURE •IDs account for a quarter of all human mortality and a similar fraction of morbidity (www.who.int/whr/2005/en/) •IDs of crops and livestock cost the global economy many billions of euros every year •Sudden epidemics of IDs can deliver humanitarian and economic shocks on a scale diffricult to absorb. * United Nations, The Millenium Development goals Report 2005, New York 2005 WB Report 2003: SARS epidemic, which killed < 1000 people, was responsible for an estimated fall of 2% in GDP across East Asia •Outbreaks of livestocks (FMD, BSE, CSF, AI… ) and crop diseases (Soybean rust, Southern corn leaf blight) costing individual countries billions of euros The UN Millenium Development goals* for reducing the burden of IDs (HIV, TB, malaria), poverty and hunger (compromised by livestock and crop diseases) are gloomy: in most developing regions, where the impacts of IDs are greatest, little hope of meeting any of these goals by 2015 *United Nations, The Millenium Development goals Report 2005, New York 2005 EMERGING INFECTIONS “infections that have newly appeared in a population or have existed previously but are rapidly increasing in incidence or geographic range” Morse, S. -
Neglected Tropical Diseases in The
Qian et al. Infectious Diseases of Poverty (2019) 8:86 https://doi.org/10.1186/s40249-019-0599-4 SCOPING REVIEW Open Access Neglected tropical diseases in the People’s Republic of China: progress towards elimination Men-Bao Qian1, Jin Chen1, Robert Bergquist2, Zhong-Jie Li3, Shi-Zhu Li1, Ning Xiao1, Jürg Utzinger4,5 and Xiao-Nong Zhou1* Abstract Since the founding of the People’s Republic of China in 1949, considerable progress has been made in the control and elimination of the country’s initial set of 11 neglected tropical diseases. Indeed, elimination as a public health problem has been declared for lymphatic filariasis in 2007 and for trachoma in 2015. The remaining numbers of people affected by soil-transmitted helminth infection, clonorchiasis, taeniasis, and echinococcosis in 2015 were 29.1 million, 6.0 million, 366 200, and 166 100, respectively. In 2017, after more than 60 years of uninterrupted, multifaceted schistosomiasis control, has seen the number of cases dwindling from more than 10 million to 37 600. Meanwhile, about 6000 dengue cases are reported, while the incidence of leishmaniasis, leprosy, and rabies are down at 600 or fewer per year. Sustained social and economic development, going hand-in-hand with improvement of water, sanitation, and hygiene provide the foundation for continued progress, while rigorous surveillance and specific public health responses will consolidate achievements and shape the elimination agenda. Targets for poverty elimination and strategic plans and intervention packages post-2020 are important opportunities for further control and elimination, when remaining challenges call for sustainable efforts. Keywords: Control, Elimination, People's Republic of China, Neglected tropical diseases Multilingual abstracts deprived urban settings [1, 2].